drugset / Trial / NCT02565511
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Phase 2/3
Terminated
480 enrolled
Novartis Pharmaceuticals
Amgen · collabBanner Alzheimer's Institute · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Timeline
- Start
- 2015-11-30
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMILOMOTIDE | Protein / enzyme biologic | 450 ug | Intramuscular |
| Subject | CNP520 | Unknown | 50 mg | Oral |